[The role of "hemochromatosis alleles" in the pathogenesis of polyglobulia after renal transplantation].
43 kidney recipients were followed up for 12 months after renal transplantation. In 13 patients treated with cyclosporin A for 6 months polyglobulia was found, which subsided after conversion of immunosuppressive therapy. A highly significant correlation was found between the presence of the antigen A3 and the polyglobulia in kidney recipients treated by cyclosporin A. The serum ferritin level was not elevated in kidney recipients who were carriers of the "hemochromatosis alleles". Results obtained in this study seem to justify the following conclusions: 1. Kidney recipients who are carriers of "hemochromatosis alleles" show a threefold higher risk of posttransplant polyglobulia. 2. Presence of "hemochromatosis alleles" is not an absolute predictor of polyglobulia in patients after kidney transplantation. 3. Both etiology and pathogenesis of posttransplant polyglobulia do not seem to be homogeneous. Cyclosporin A, in contrast to azathioprine, seems to have a promoting effect on the development of posttransplant polyglobulia. Therefore treatment of kidney transplant patients with cyclosporin A, who are carriers of "hemochromatosis alleles", needs careful monitoring.
D000328:Adult; D000483:Alleles; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006432:Hemochromatosis / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000209:etiology* / Q000503:physiopathology
D016572:Cyclosporine
Rola"allelihemochromatozy" w patogenezie poliglobulii po transplantacji nerki.